《睡眠專業人士雜誌》
星期四, 七月 23, 2026
Panthera Dental is pleased to announce a remarkable milestone in its ongoing commitment to innovation and excellence: the company now holds over 110 patents across the dental, medical, and sleep appliance industries. This significant milestone follows their recent amicable settlement with ResMed SAS that resolves all ongoing patent infringement litigation […]
Harmony Biosciences announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of excessive daytime sleepiness (EDS) in pediatric patients six years of age and older with narcolepsy. The FDA separated the submission into two sNDAs […]
ProSomnus, Inc. announced it has initiated a voluntary restructuring process under Chapter 11 of the U.S. Bankruptcy Code to reorganize and strengthen its capital structure going forward, improve financial flexibility and better position the company for long-term success. In connection with this process, the Company has secured the support of […]
Panthera Dental proudly announces that two distinct abstracts were accepted for poster presentations at the AADSM and AASM/SLEEP Annual Meetings. In addition, a funding opportunity through Panthera for investigator-initiated research proposals will be announced. The posters and the “Panthera Sleep Research Grant” reflect Panthera’s dedication to advancing dental sleep medicine […]
Centessa Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) to initiate a Phase 1 first-in-human clinical trial of ORX750 for the treatment of narcolepsy. ORX750 is an investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist […]
Harmony Biosciences Holdings, Inc. has announced an exclusive licensing agreement with Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor (OX2R) agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders. TPM-1116 represents a new chemical series of OX2R agonists […]
Axsome Therapeutics, Inc. has announced that AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, achieved the primary endpoint and significantly reduced the frequency of cataplexy attacks as compared to placebo in patients with narcolepsy in the SYMPHONY Phase 3 trial. AXS-12 also reduced excessive […]
As the prevalence of atrial fibrillation (AF) continues to rise, particularly among the aging population, its connection with obstructive sleep apnea (OSA) has become increasingly evident.1 Patients with AF seeking treatment for OSA often present with a complex medical history that includes a number of comorbidities, such as hypertension, acid […]
Takeda has announced positive topline results from a randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1. Narcolepsy is a chronic, rare neurological disorder of central hypersomnolence with significant unmet need despite multiple approved therapies. It is […]
– SynAIRgy Compares AD109 to Placebo Over 6 Months in People with OSA who Are Intolerant of or Refuse Positive Airway Pressure (PAP) Therapy, the Current Standard of Care – Part of a two-study registrational Phase 3 program that also includes LunAIRo which began enrollment in 九月 2023 Apnimed, Inc., […]
